Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice (original) (raw)
Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F . (2005). Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res65: 4005–4011. ArticleCAS Google Scholar
Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L . (2001). Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol21: 2144–2153. ArticleCAS Google Scholar
Castresana JS, Rubio MP, Vasquez JJ, Idoate M, Sober AJ, Seizinger BR et al. (1993). Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer55: 562–565. ArticleCAS Google Scholar
Chang DL, Qiu W, Ying H, Zhang Y, Chen CY, Xiao ZX . (2007). ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2. Oncogene26: 4627–4634. ArticleCAS Google Scholar
Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C et al. (1997). Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev11: 2822–2834. ArticleCAS Google Scholar
Christophorou MA, Ringshausen I, Finch AJ, Swigart LB, Evan GI . (2006). The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature443: 214–217. ArticleCAS Google Scholar
Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM et al. (2006). A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell10: 459–472. ArticleCAS Google Scholar
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med353: 2135–2147. ArticleCAS Google Scholar
Dai DL, Martinka M, Li G . (2005). Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol23: 1473–1482. ArticleCAS Google Scholar
Dhawan P, Singh AB, Ellis DL, Richmond A . (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res62: 7335–7342. CASPubMed Google Scholar
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA92: 9363–9367. ArticleCAS Google Scholar
Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R et al. (2006). Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer95: 581–586. ArticleCAS Google Scholar
Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG . (2006). Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol126: 154–160. ArticleCAS Google Scholar
Gray-Schopfer VC, Cheong SC, Chong H, Chow J, Moss T, Abdel-Malek ZA et al. (2006). Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer95: 496–505. ArticleCAS Google Scholar
Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V . (2006). Genetic alterations in signaling pathways in melanoma. Clin Cancer Res12: 2301s–2307s. ArticleCAS Google Scholar
Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA . (2003). Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res63: 5198–5202. CAS Google Scholar
Laud K, Marian C, Avril MF, Barrois M, Chompret A, Goldstein AM et al. (2006). Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet43: 39–47. ArticleCAS Google Scholar
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med350: 2129–2139. ArticleCAS Google Scholar
Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature436: 720–724. ArticleCAS Google Scholar
Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, McKee PH, Chin L et al. (2006). Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer45: 447–454. ArticleCAS Google Scholar
Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD et al. (2005). BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol15: 249–254. ArticleCAS Google Scholar
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003). High frequency of BRAF mutations in nevi. Nat Genet33: 19–20. ArticleCAS Google Scholar
Pollock PM, Meltzer PS . (2002). A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell2: 5–7. ArticleCAS Google Scholar
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L et al. (1998). The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell92: 713–723. ArticleCAS Google Scholar
Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA . (1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell85: 27–37. ArticleCAS Google Scholar
Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP . (2005). Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res65: 2412–2421. ArticleCAS Google Scholar
Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L . (2003). Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene22: 5055–5059. ArticleCAS Google Scholar
Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW et al. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res64: 7002–7010. ArticleCAS Google Scholar
Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlow SJ, Easty DJ et al. (2002). p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst94: 446–454. ArticleCAS Google Scholar
Tamura A, Halaban R, Moellmann G, Cowan JM, Lerner MR, Lerner AB . (1987). Normal murine melanocytes in culture. in vitro Cell Dev Biol23: 519–522. ArticleCAS Google Scholar
Tief K, Schmidt A, Beermann F . (1998). New evidence for presence of tyrosinase in substantia nigra, forebrain and midbrain. Brain Res Mol Brain Res53: 307–310. ArticleCAS Google Scholar
Tonks ID, Nurcombe V, Paterson C, Zournazi A, Prather C, Mould AW et al. (2003). Tyrosinase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelial-derived tissues. Genesis37: 131–138. ArticleCAS Google Scholar
Tsao H, Goel V, Wu H, Yang G, Haluska FG . (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol122: 337–341. ArticleCAS Google Scholar
Uribe P, Andrade L, Gonzalez S . (2006). Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol126: 161–166. ArticleCAS Google Scholar
Wu H, Goel V, Haluska FG . (2003). PTEN signaling pathways in melanoma. Oncogene22: 3113–3122. ArticleCAS Google Scholar
Zhang Y, Xiong Y, Yarbrough WG . (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell92: 725–734. ArticleCAS Google Scholar